Will the J&J vaccine 'pause' build trust in vaccine safetyâor fuel vaccine hesitancy?
The
Advisory Committee on Immunization Practices (ACIP), a panel of outside experts that advises CDC on vaccines, on Wednesday declined to vote on whether use of
Johnson & Johnson's (J&J) single-dose vaccine should resume—leaving the federal government's recommended pause in place until the committee's next meeting, which is expected within 10 days.
ACIP declines to vote on whether to resume use of J&J's vaccine
CDC and
FDA in a statement Thursday recommended a pause in the use of J&J's single-dose Covid-19 vaccine after six people—out of about 6.8 million Americans who have received the vaccine so far—developed a rare and severe type of blood clot called cerebral venous sinus thrombosis (CVST) six to 13 days after vaccination. According to the statement, the agencies recommended the pause "out of an abundance of caution" as CDC and FDA scientists examine the potential link between the vaccine and CVST.